Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Loss and Comprehensive Loss (Unaudited)

v3.22.2.2
Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
EXPENSES        
Research and development $ 9,869 $ 4,591 $ 21,464 $ 19,460
General and administrative 2,770 2,102 8,474 6,519
Total operating expenses 12,639 6,693 29,938 25,979
OTHER INCOME (EXPENSE)        
Interest income 73 3 81 14
Interest expense [note 7] (481)   (1,242)  
Other income (expense) (30) (1) (19) (36)
Total other (expense) (438) 2 (1,180) (22)
Net loss and comprehensive loss $ (13,077) $ (6,691) $ (31,118) $ (26,001)
Basic net loss per common share [note 8[d]] $ (1.35) $ (0.71) $ (3.24) $ (3.39)
Diluted net loss per common share [note 8[d]] $ (1.35) $ (0.71) $ (3.24) $ (3.39)
Weighted average shares used in computation of basic net loss per common share [note 8[d]] 9,693,788 9,452,238 9,600,947 7,670,383
Weighted average shares used in computation of diluted net loss per common share [note 8[d]] 9,693,788 9,452,238 9,600,947 7,670,383